TLDR
- WORK stock tumbles 23% after-hours ahead of reverse split plans.
- 1-for-100 split aims to restore Nasdaq compliance this October.
- Company confirms all shareholders impacted equally in split.
- Shares to trade under “WOK” ticker post-split on October 21.
- WORK continues global growth in medical device manufacturing.
WORK Medical Technology Group LTD experienced a sharp shift in its stock performance on October 17, 2025. The stock gained 1.56% in regular trading, closing at $0.0586. After-hours trading brought a 23.04% plunge, pushing the stock down to $0.0451.
This volatile price action occurred just days before the company’s planned 1-for-100 reverse stock split. Scheduled for October 21, 2025, the reverse split aims to boost the stock’s price to meet Nasdaq’s minimum bid requirement. The company confirmed that post-split trading will continue under the “WOK” ticker with a new CUSIP number.
The split received board and shareholder approval and targets compliance with Nasdaq Marketplace Rule 5550(a)(2). The company will combine every 100 existing shares into a single share. The adjustment will apply to both Class A and Class B shares on the effective date.
Company Confirms Reverse Stock Split to Regain Nasdaq Compliance
WORK Medical Technology Group will proceed with a 1-for-100 reverse stock split on October 21, 2025. This move follows regulatory pressure to meet Nasdaq’s minimum bid price rule. The company’s shares have traded under $1.00, triggering non-compliance status.
The action will reduce Class A shares from approximately 96 million to 960,000. Likewise, Class B shares will shrink from 7.59 million to roughly 76,000. All shareholders will be affected uniformly, and fractional shares will be rounded up.
The company stated that the reverse split does not change ownership percentages. It only alters the number of shares held by each party. The primary goal remains to regain and maintain Nasdaq listing compliance.
WORK Medical Remains Focused on Medical Device Operations
WORK Medical Technology Group operates through its Chinese subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. The company manufactures and distributes Class I and II medical devices and consumables across China. Its product line includes 21 SKUs, such as multifunctional masks and disposable items.
Products are sold in all 34 provincial-level regions in China. Additionally, 15 products reach markets in over 30 countries worldwide. The company also holds FDA registrations for 17 products, enabling access to the U.S. healthcare market.
Its manufacturing arm holds multiple quality certifications. These include designations critical to regulatory approvals and global expansion. The company remains committed to medical innovation and production scale.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
